Cannabis has been used for millennia to treat many conditions. It has long been known that cannabis can help with pain, depression, and was even used in ancient China as an anesthetic for surgery.
It has also been recognized millennia ago as a potential treatment for epilepsy. However, it wasn’t until recently that we have had the scientific studies to back those beliefs up.
It all began with a girl named Charlotte Figi. Charlotte has a rare form of epilepsy known as Dravet Syndrome. At just three months old, Charlotte had her first seizure. The seizure lasted half an hour. It only got worse from there; as Charlotte got older, the number and severity of her daily seizures increased. Some of the seizures lasted up to four hours.
By the time that Charlotte was two, she began showing signs of cognitive decline and displaying signs of autistic behavior. She had aggressive outbursts, would injure herself, and was reluctant to make eye contact. At one time, Charlotte was having up to three hundred grand mal seizures a week, despite being on heavy duty anti-seizure medications. At times, her heart stopped during the seizures. Charlotte’s parents and doctors eventually put her into a medically induced coma to allow her to recuperate. They even signed a do-not-resuscitate order in the event that something went horribly wrong.
Then, Charlotte’s grandfather started reading several success stories from parents who were using cannabis to treat their children’s seizures. Another boy with Dravet’s Syndrome and his story stood out. Charlotte’s doctors had said that they had done all they could. In desperation, her parents got a hold of some R4 cannabis extract oil for Charlotte. A miracle occurred. Charlotte went from 300 seizures a week to zero seizures during her first week of treatment. Seeing that the cannabis treatment was helping, Charlotte’s parents reached out to the Stanley Brothers, who run medical marijuana farms and dispensaries in Colorado. They created Charlotte’s Web, a hybrid strain of medical marijuana, which contained a 30:1 mixture of CBD to THC.
After Charlotte’s success story came a number of others. All from parents whose children were helped by Charlotte’s Web and other high-CBD cannabis treatments. Anecdotal stories are one thing, but is there scientific evidence? The answer to that is yes.
In 2016, Orrin Devinsky, a neurologist at New York University Langone Medical Center and colleagues across multiple research centers published the results from a study of a cannabis-based drug for treatment-resistant epilepsy in the journal Lancet Neurology. 162 patients were treated with an extract of 99% cannabidiol (CBD) and monitored them for 12 weeks. The treatment was given in conjunction with existing medications.
The results were more than promising. The treatment resulted in the reduction of motor seizures that was comparable to similar drugs. 2% of patients reported being seizure- free. The trial led by Devinsky was the most robust assessment of CBD’s effect on epilepsy. Unfortunately, these trials were open trials and had no controlled factors.
However, more recently, the Food and Drug Administration approved a highly purified oral preparation of CBD. In the open label expanded access programs as well as placebo-controlled trials, there was a significant improvement in seizure frequency when compared to the placebo patients with Dravet Syndrome and Lennox-Gastaut Syndrome. The drug that has been approved by the FDA is the prescription medication known as Epidolex.
The results from the gold-standard studies of Epidolex were extremely promising. In the group receiving 20 mg of CBD twice daily, the occurrence of seizures dropped 41.9%. In those receiving the 10 mg dose, seizures dropped by 37.2%. In the placebo group, seizures dropped by 17.2%. Like with all other medications, even treatment with CBD oil has its side effects. For the most part, the side effects are well tolerated and only a few patients experienced side effects serious enough to stop taking the medication. The most commonly reported side effects were sedation, decreased appetite, and diarrhea.
When it comes to the legality of CBD treatments, especially those not approved by the FDA, there is good news. The passage of the 2018 Farm Bill hemp and hemp-derived substances are exempt from the Controlled Substances Act. This includes CBD oil, which can be purchased at places like TheAmsterdam. Even though it has been legalized, it is important that any parent or patient speak with their doctors before beginning any treatment.
Core One Labs’ Subsidiary, Core Isogenics Inc., Teams up with Reiziger Pty. Ltd. to Showcase High Yielding Nutritional Cultivation Technology
Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) (“COOL” or the “Company”) announces that its wholly-owned subsidiary, Core Isogenics Inc., has begun a highly complex nutritional regimen to accelerate the growth of cannabis plants and increase flower yield and quality.
The Core Isogenics’ nursery and breeding rooms are now operational. Approximately 25% of the breeding rooms are now actively involved in a project with Reiziger® Holland to improve harvest yields. This is a significant milestone in the Company’s journey to seed-to-sale with increased profitability. The initial project focus will be a twelve-month study matching genetics to nutrients and creating feeding regimens specifically designed for maximum absorption and conversion of nutrients into cannabinoids. The Company has high expectations for this technology and the possible benefits for the CannaStrips™ brand.
The nursery facility is uniquely suited for this type of project with its ability to track the growing conditions in isolated rooms, as well as documenting the feeding schedule and soil condition in order to gather information to accurately assess the cultivation process. This documentation will allow the Company to consistently produce high quality products in every harvest. This consistency is vital to the Company’s cultivation model where the goal is a predictable outcome in every harvest.
CEO of Core One Labs Inc., Brad Eckenweiler, stated, “The introduction of Reiziger® and their cultivation technology into our operation is a major step in the growth of Core One Labs. The ability to have Shaun Reid and his team of master Dutch breeders and growers share their decades of experience is extremely valuable and will result in accelerating the Core Isogenics nursery years ahead of what would have been a long learning curve. Most certainly our indoor growing ability will be the primary beneficiary with higher yields and stronger cannabinoid profiles.” The Company will continue to update the market on the development of this exciting project.
SOURCE Core One Labs Inc.
IMCC Appoints Yaron Berger as CEO of IMC Holdings
IM Cannabis Corp. (the “Company” or “IMCC”) (CSE: IMCC), one of the world’s pioneering medical cannabis companies with operations across Europe, is pleased to announce the appointment of Yaron Berger as Chief Executive Officer of I.M.C. Holdings Ltd. (“IMC“), the Company’s wholly-owned operating subsidiary in Israel. Oren Shuster will remain the Chief Executive Officer of IM Cannabis Corp.
Mr. Berger brings more than 10 years of experience in various senior roles both in public and private sectors, leading large-scale operations. Most recently, Mr. Berger was the Chief Executive Officer of Telepharma Ltd. (“Telepharma,” doing business as epharma), a leading wholesaler, direct marketer of prescription drugs and chain of pharmacies in Israel. At Telepharma, among other accomplishments, Mr. Berger re-branded its digital platform and transformed the customer experience. As an early entrant into the medical cannabis sector, Mr. Berger also established Greenpharma under Telepharma, a full-service distributor, patient counselling service provider and online resource for medical cannabis patients in Israel. Prior to his experience in the pharmaceutical sector, Mr. Berger served as the Chief Operating Officer of the National Police Academy and spent over 20 years in the Israeli Air Force, most recently as a Lieutenant Colonel.
Oren Shuster, Chief Executive Officer of IMCC said “Yaron is uniquely qualified to lead our Israeli operations under the new medical cannabis regulatory regime, which requires a high level of engagement and education for the country’s pharmacists on the benefits of medical cannabis. Yaron was an early mover in identifying the opportunity in medical cannabis and we are very excited to benefit from his expertise in the pharmacy channel to maintain IMC’s status as a leading medical cannabis brand in Israel.”
“I am thrilled to be joining the IMC team, who I have known as a leader in the medical cannabis market in Israel over the past ten years,” said Mr. Berger. “The IMC brand is synonymous with quality and innovation. The new medical cannabis reform in Israel presents a significant opportunity for the Company and the IMC brand to further elevate its market position as the preferred medical cannabis brand for physicians, pharmacists and patients.”
SOURCE IM Cannabis Corp.
LCBO’s bottom line proves privatized alcohol sales a bad idea: OPSEU’s Thomas
The LCBO’s latest profits show the Crown corporation’s value to the people of Ontario, OPSEU President Warren (Smokey) Thomas said Friday.
In its 2018/2019 annual report released Thursday, the LCBO is reporting earnings of $2.37 billion on total revenue of $6.39 billion.
Thomas said those profits go to the provincial government and pay for vital public services like health, education and highways.
“This is why the Ford government should rethink allowing corner stores and grocery stores to sell more alcohol,” said Thomas. “Is saving folks a 10 minute drive in some cases worth jeopardizing their health care?”
OPSEU represents LCBO workers and Thomas says these frontline professionals deserve the credit for the corporation’s continued success.
“The reason the LCBO is the gold standard in selling alcohol responsibly is because of OPSEU members who make sure alcohol isn’t sold to minors or intoxicated people,” said Thomas.
“They also provide customer service that is second to none and they’re the ones who have made the LCBO a success story.”
As he read the LCBO report, OPSEU First Vice-President/Treasurer Eduardo (Eddy) Almeida reflected on the Ford government’s decision to take the sale of legalized cannabis away from the Crown Corporation.
“Think of what the LCBO’s profits would have been if Premier Ford hadn’t scrapped the plan of the former Liberal government?” said Almeida. “I’ve put together a lot of budgets and I know how tough an exercise it is.”
“It still makes me shake my head that a government that claimed it had catastrophic financial problems would turn down massive amounts of revenue and go on the misguided course that the Conservatives took. Really? Wow.”
Almeida says municipalities who voted to opt out of Doug Ford’s foolish cannabis privatization plan should stand firm and demand a responsible plan.
“The LCBO continues to prove it’s the best option to keep controlled substances out of the hands of minors,” said Almeida. “Municipalities and Ontarians in general should continue to demand a responsible plan and just say no to Doug’s. After all, a little competition wouldn’t be a bad thing would it?”
SOURCE Ontario Public Service Employees Union (OPSEU)
Cannabis3 weeks ago
Khiron Launches Kuida Brand in the US, Begins First Sales
Cannabis3 weeks ago
Cannabis Growth Opportunity Corporation Announces NAV of $2.51
Cannabis3 weeks ago
AMP German Cannabis Group Receives an Import Licence for Medical Cannabis from the German State of Thuringia
Cannabis4 weeks ago
Harvest Health & Recreation Inc. Unveils CannApprove™ Testing and Safety Protocols for Harvest THC Vape Products
Cannabis3 weeks ago
Illinois Scores Best-Selling Cookies Strains in 2020, via Ascend Wellness Holdings
Cannabis4 weeks ago
PodCo Media Networks Launches Three New Business Podcast Series: Deep Dive, Citizen CEO and Uncharted UX
Cannabis4 weeks ago
AC Braddock Nominated for 2019 Industry Impact Award
Cannabis3 weeks ago
Avicanna Reports Third Quarter 2019 Financial Results